Cite
HARVARD Citation
Wang, X. et al. (n.d.). 92P Neoadjuvant multimodality RX including immunotherapy for highly selective unresectable locally advanced esophageal squamous cell carcinoma (NEXUS): A prospective, single-arm, phase II trial. Immuno-oncology technology. p. . [Online].